Immunome Inc.
IMNM · XNASCIK 1472012fmd_0CSM7VSHNJ10GZM8XR012V6Q1CManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 29 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 14 | 9 | 7 |
| Net interest income | (0) | (0) | (0) | 0 | 3 | 13 | 12 |
| Research and development | 9 | 7 | 14 | 23 | 23 | 130 | 177 |
| Total operating expenses | 10 | 12 | 25 | 37 | 124 | 315 | 231 |
| Operating income | (10) | (12) | (25) | (37) | (110) | (306) | (224) |
| Interest expense | 0 | 0 | – | – | – | – | – |
| Other non-operating income (expense) | – | (6) | 0 | 0 | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (10) | (18) | (25) | (37) | (107) | (293) | (212) |
| Net income to common shareholders | – | – | (25) | (38) | (107) | (293) | (212) |